Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
Sıva, Aksel , Landes-Château, Cassandre , Mondot, Lydiane, Papeix, Caroline , Thouvenot, Éric , Labauge, Pierre, Durand‐Dubief, Françoise , Page, Emmanuelle Le , Terzi, Murat , Derache, Nathalie, Bourre, Bertrand , Hoepner, Robert , Karabudak, Rana , Ciron, Jonathan , Wiertlewski, Sandrine, Turan, Ömer Faruk , Yucear, Nur, Cohen, Mikaël , Azevedo, Christina , Kantarci, Orhun H. , Pelletier, Daniel , Group, TERIS Study, Branger, Pierre , Abrous, Mouloud, Petit, Julie, Gelet, Céline, Russello, Mélanie, Gaultier, Alina, Frère, Fabienne Le, Callier, Céline, Caillon, Cynthia, Gueydan, Eglantine, Louapre, Céline , Galanaud, Damien , Ungureanu, Aurelian , Coudoin, Sylvie, Hébant, Benjamin , Gerard, Emmanuel, Vimont, Christine, Bonneville, Fabrice , Freitas, Noellie, Kilic, Erhan , Destan, Sena, Friedli, Christoph , Wagner, Franca , Weber, Lea , Tchoubar, Annaig, Dumont, Émilie , Eryilmaz, Asli, Roman, Tanguy, Pelletreau, Christopher, Grateau, Aurélie, Mathieu, Yanica, Yaïche, Sarhan, Rintelen, Felix, Firmino, Isabel, Chastenier, Aymeric De, Gheribenblidia, Amel, Zeydan, Burcu , Siva, Aksel , Zeydan, Burcu , Thouvenot, Eric , Ciron, Jonathan , Durand-Dubief, Françoise , Cohen, Mikaël , Lebrun‐Frénay, Christine , Sormani, Maria Pia , Mondot, Lydiane , Bovis, Francesca , Vermersch, Patrick , Labauge, Pierre , Efendi, Hüsnü , Bourre, Bertrand , Seze, Jerome De , Clavelou, Pierre , Okuda, Darin T. , Group, TERIS Study, Zéphir, Hélène , Vukusic, Sandra , Carra‐Dallière, Clarisse , Ayrignac, Xavier , Laplaud, David , Biotti, Damien , Duman, Taşkın , Tütüncü, Melih , Uygunoğlu, Uğur , Şen, Sedat , Weber, Lea, Eryılmaz, Aslı

Mayo Clinic

JAMA Neurology | August 21, 2023 | Volume: 80 | Issue: 10 | Pages: 1080

10.1001/jamaneurol.2023.2815 | PMID 37603328 Get It

Importance Radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS) punctuated by incidental magnetic resonance imaging (MRI) white matter anomalies within the central nervous system. Objective To determine the time to onset of symptoms consistent with MS. Design, Setting, and Participants From September 2017 to October 2022, this multicenter, double-blind, phase 3, randomized clinical trial investigated the efficacy of teriflunomide in delaying MS in individuals with RIS, with a 3-year follow-up. The setting included referral centers in France, Switzerland, and Turkey. Participants older than 18 years meeting 2009 RIS criteria were randomly assigned (1:1) to oral teriflunomide, 14 mg daily, or placebo up to week 96 or, optionally, to week 144. Interventions Clinical, MRI, and patient-reported outcomes (PROs) were collected at baseline and yearly until week 96, with an optional third year in the allocated arm if no symptoms have occurred. Main outcomes Primary analysis was performed in the intention-to-treat population, and safety was assessed accordingly. Secondary end points included MRI outcomes and PROs. Results Among 124 individuals assessed for eligibility, 35 were excluded for declining to participate, not meeting inclusion criteria, or loss of follow-up. Eighty-nine participants (mean [SD] age, 37.8 [12.1] years; 63 female [70.8%]) were enrolled (placebo, 45 [50.6%]; teriflunomide, 44 [49.4%]). Eighteen participants (placebo, 9 [50.0%]; teriflunomide, 9 [50.0%]) discontinued the study, resulting in a dropout rate of 20% for adverse events (3 [16.7%]), consent withdrawal (4 [22.2%]), loss to follow-up (5 [27.8%]), voluntary withdrawal (4 [22.2%]), pregnancy (1 [5.6%]), and study termination (1 [5.6%]). The time to the first clinical event was significantly extended in the teriflunomide arm compared with placebo, in both the unadjusted (hazard ratio [HR], 0.37; 95% CI, 0.16-0.84; P = .02) and adjusted (HR, 0.28; 95% CI, 0.11-0.71; P = .007) analysis. Secondary imaging end point outcomes including the comparison of the cumulative number of new or newly enlarging T2 lesions (rate ratio [RR], 0.57; 95% CI, 0.27-1.20; P = .14), new gadolinium-enhancing lesions (RR, 0.33; 95% CI, 0.09-1.17; P = .09), and the proportion of participants with new lesions (odds ratio, 0.72; 95% CI, 0.25-2.06; P = .54) were not significant. Conclusion and Relevance Treatment with teriflunomide resulted in an unadjusted risk reduction of 63% and an adjusted risk reduction of 72%, relative to placebo, in preventing a first clinical demyelinating event. These data suggest a benefit to early treatment in the MS disease spectrum. Trial Registration ClinicalTrials.gov Identifier: NCT03122652
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Hsu, Chih–Yuan , Shah, Surbhi, Zon, Rebecca L. , Alsamarai, Susan, El-Bakouny, Ziad, Beeghly, Alicia, Doroshow, Deborah B. , Flora, Daniel , Fromowitz, Ariel, Jani, Chinmay , Khan, Hina, Klein, Elizabeth J. , Heater, Natalie Knox , Koshkin, Vadim S. , Kwon, Daniel H. , McKay, Rana R. , Nonato, Taylor K., Polimera, Hyma , Puc, Matthew , Shastri, Aditi , Singh, Sunny , Weissmann, Lisa B., Wilkins, Cy R. , Yoon, James J., Mishra, Sanjay , Grivas, Petros , Connors, Jean M. , Gandhi, Rikin, Gartrell, Benjamin A. , Makower, Della , Sullivan, Darciann O', Ohri, Nitin , Verma, Amit , Butt, Omar H. , Fiala, Mark A. , Monahan, Ryan, Bitran, Jacob D. , Hallmeyer, Sigrun , Mundt, Daniel , Pandravada, Sasirekha, Papaioannou, Philip V., Patel, Mauli, Streckfuss, Mitrianna, Tadesse, Eyob, Lammers, Philip E. , Bindal, Poorva , Lam, Barbara C.C., Piper‐Vallillo, Andrew J., Arvanitis, Panos , Vieira, Kendra, Angevine, Anne H., Bär, Michael, Prete, Salvatore A. Del , Fiebach, Maryann Z., Gulati, Anthony P., Hatton, Edward H., Houston, Kaly, Lo, K. M. Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Routy, Bertrand , Hoyo-Ulloa, Irma , Gupta, Shilpa , Sharifi, Nima , Hoppenot, Claire , Demetri, George D., Zarif, Talal El , Freeman, Dory , Nohria, Anju, Tolaney, Sara M. , Zhang, Tian , Dzimitrowicz, Hannah, Leighton, John, Lynch, Ryan C. , Portuguese, Andrew J. , Schweizer, Michael T. , Vinayak, Shaveta , Wagner, Michael J. , Dansoa, Yvonne , Manikowski, Jesse J. , Vadakara, Joseph , Yossef, Kristena, Beckerman, Jennifer, Goyal, Sharad , Messing, Ian , Provenzano, Destie , Steffes, Dawn R., Clément, Jessica , Cosin, Jonathan A. , Daher, Ahmad , Dailey, Mark E., Hosmer, Wylie, Hsu, Emily , Jayaraj, Asha, Mather, Jeff, Menendez, Alvaro G. , Nadkarni, Rajani, Serrano, Oscar K. , Tejwani, Sheela , Accordino, Melissa , Bodin, Brianne E, Khan, Shaheer , Masson, Cynthia, Alexander, Mariam , Matar, Sara , Bernicker, Eric , Deeken, John F. , Jeffords, Kelly J., Shafer, Danielle , Cárdenas‐Delgado, Ana I., Campos, Rogelio Cuervo, Ramirez, Ana, Valdez-Reyes, Nadia Melissa, Gill, David , Lewis, Mark A. , Low, Clarke A., Rhodes, Terence D., Jones, Michelle, Mansoor, Abdul-Hai, Mashru, Sandeep H., Werner, Mica A., Cohen, Aaron , Hayes‐Lattin, Brandon , Nemecek, Eneida R. , Williamson, Staci, Lewis, Grant C., Smith, Stephanie J., Akhtari, Mojtaba, Castillo, Dan R., Cortez, Kimberly, Park, Kyu, Reeves, Mark E. , O’Connor, Timothy E. , Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Ramesh, Vidhyalakshmi , Wilson, Grace L. , Bardia, Aditya , Gainor, Justin F. , Peppercorn, Jeffrey , Reynolds, Kerry L. , Zubiri, Leyre , Campian, Jian , Riaz, Irbaz B, Williams, Colt , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Wang, Chen‐Pin , Bouganim, Nathaniel , Elkrief, Arielle , Moria, Feras, Panasci, Justin , Nanchal, Rahul , Bahadur, Nadia , Nambiar, Puja H. , Papadopoulos, Esperanza B. , Riely, Gregory J. , Rosenberg, Jonathan E., Cerrone, Kim, Dill, Jennifer A. , Faller, Bryan A. , Ajmera, Archana , Brouha, Sharon S. , Choi, Sharon , Bhatt, Padmanabh , Mariano, Melissa G., Thomson, Carey C. , Glace, Mary Grace, Knoble, Jeanna, Zacks, Rosemary, Blau, Sibel , Brown, CarrieAnn, Namburi, Swathi, Pomerantz, Lauren , Rovito, Marc A., Advani, Pragati E., Cronin, Tara, Fleissner, Bridget, Goel, Shipra , Gopalakrishnan, Dharmesh , Hernandez‐Ilizaliturri, Francisco J. , Kariapper, Ariffa, Levine, Ellis , Wicher, Camille P., Misdary, Christian, Shah, Mansi , Batist, Gerald , Cook, Erin , Esfahani, Khashayar , Ferrario, Cristiano , Lau, Susie , Ma, Kim, Rudski, Lawrence , Dutra, Míriam Santos , Mahmood, Sana , Mico, Vasil, Rivera, Andrea Verghese, Dixon, Becky, Heilman, Hannah, Logan, Barbara, Mandapakala, Chaitanya, Cabebe, Elwyn C., Glover, Michael , Jha, Alokkumar , Schapira, Lidia , Shah, Sumit , Subbiah, Suki , Lopes, Gilberto , Cardenas, Karen de, Russell, Karen , Stith, Brittany, Taylor, Sharona, Klamerus, Justin F., Revankar, Sanjay G. , Addison, Daniel , Chen, James L. , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Abbasi, Saqib Hussen, Annis, Sandy, Greenland, Steven, Jones, Regina, Kasi, Anup , Rock, Crosby D. , Wulff‐Burchfield, Elizabeth , Smits, Melissa, Weiß, Matthias , Chism, David D. , Owenby, Susie, Ang, Celina , Galsky, Matthew D. , Metzger, Megan , Uyehara, Catherine, Lashley, Latoya N., Sueyoshi, Mark, Patel, Kanishka G. , Riess, Jonathan W. , Borno, Hala T. , Rubinstein, Samuel M. , Ahmad, Syed A. , Grover, Punita , Jandarov, Roman , Kharofa, Jordan , Marcum, Michelle, Sohal, Davendra , Zamulko, Olga , Balmaceda, Nicole , Geiger, Christopher L., Russ, Atlantis Dawn, Saker, Haneen , Choi, Horyun, Feldman, Lawrence , Gantt, Gerald, Hoskins, Kent , Khan, Mahir, Liu, Li , Nguyen, Ryan H., Schwartz, Candice, Venepalli, Neeta K. , Boldt, Anne, Fecher, Leslie A. , Su, Chris, Bijjula, Ragneel R., Mavromatis, Blanche H., Seletyn, Mildred E., Wood, Barbara R., Kaklamani, Virginia , Charles, Lawrence J., Cheng, Alex , Ding, Tan , Enriquez, Kyle T. , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Lewis, Judy T., Reid, Sonya , Saif, Sara, Slosky, David, Solórzano, Carmen C. , Sun, Tianyi , Yang, Yuanchu James , Carducci, Theresa M., Goldsmith, Karen J., Loon, Susan Van, Topaloĝlu, Ümit , Moore, Joan K., Cabalona, Wilhelmina D., Shisler, Elizabeth, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Bilen, Mehmet Asım , Castellano, Cecilia A. , Ravindranathan, Deepak , LoRusso, Patricia , Lustberg, Maryam B. , Masters, Tyler, Mishra, Sanjay , Zubiri, Leyre , Fiala, Mark A , Bilen, Mehmet A , Portuguese, Andrew J , Lustberg, Maryam , Gulati, Shuchi , Shah, Pankil , Awosika, Joy A. , Bashir, Babar , Berg, Stephanie , De‐la‐Rosa‐Martinez, Daniel , Egan, Pamela , Fein, Joshua Alexander , Friese, Christopher R. , Griffiths, Elizabeth A. , Hwang, Clara , Joshi, Monika , Labaki, Chris , Latif, Tahir , Nagaraj, Gayathri , Nakasone, Elizabeth S. , Razavi, Pedram , Ruíz‐García, Erika , Saliby, Renée Maria , Tagalakis, Vicky , Vilar‐Compte, Diana , Wise-Draper, Trisha Michel , Wotman, Michael T. , Shyr, Yu , Warner, Jeremy L. , Shah, Dimpy P. , Rosovsky, Rachel , Goel, Sanjay , Halmos, Balázs , Sica, Roberto Alejandro , Henderson, Jeffrey P. , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Thompson, Michael A. , Loree, Jonathan M. , Lam, Barbara, Peters, Mary Linton B , Farmakiotis, Dimitrios , Olszewski, Adam J. , Hatton, Edward, Rose, Suzanne J. , Nizam, Amanda , Pennell, Nathan A , Li, Ang , Bitterman, Danielle S. , Choueiri, Toni K. , Florez, Narjust , Giordano, Antonio , Morgans, Alicia K. , Nohria, Anju , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Graber, Jerome J. , Hawley, Jessica E. , Loggers, Elizabeth T , Lyman, Gary H , Su, Christopher , Tachiki, Lisa , Yeh, Albert C. , Gatson, Na Tosha , Makary, Mina S. , Rao, Yuan James , Rosenstein, Lori J. , Elias, Rawad , Eton, Omar , Yu, Peter Paul , Gadgeel, Shirish M. , Bhutani, Divaya , Hershman, Dawn L. , Ingham, Matthew , Schwartz, Gary K. , Reuben, Daniel Y. , McWeeney, Shannon K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Sachs, Zohar , Wilson, Grace, Boland, Genevieve M. , Smith, Katherine E. , Bekaii‐Saab, Tanios , Desai, Aakash , Hálfdánarson, Þorvarður R. , Joyner, Michael J. , Senefeld, Jonathon W. , Ramirez, Amelie G , Mesa, Ruben A. , Papenburg, Jesse , Vinh, Donald Cuong , Singh, Harpreet , Bao, Ting , O'Cearbhaill, Roisin E , Philip, John, Robson, Mark E. , Rosenberg, Jonathan E., Schoenfeld, Adam Jacob , Tamimi, Rulla M. , Dill, Jennifer, Hsiao, Albert , Reid, Erin G , Rink, Cameron L. , Jain, Prantesh , Moffitt, Melissa , O’Connor, Tracey L. , Puzanov, Igor , Smith, Laurie J., Zsíros, Emese , Jabbour, Salma K , Cook, Erin, Miller, Wilson H. , Wilchesky, Machelle , McNair, Christopher M. , Khaki, Ali Raza , Nagpal, Seema , Wu, Julie , Whaley, David, Gatti-Mays, Margaret Elena , Jhawar, Sachin R. , Palmer, Joshua D. , Stover, Daniel G. , Weiss, Matthias, Berenberg, Jeffrey L. , Fazio, Alyson, Huber, Kathryn E. , Small, Eric J. , Zhang, Sylvia , Andermann, Tessa M. , Jensen, Christopher Edward , Wood, William A. , Li, Ningjing , Abidi, Maheen Z. , Bowles, Daniel W. , Markham, Merry Jennifer , Acoba, Jared David , Rho, Young Soo, Nguyen, Ryan H., Pasquinelli, Mary M. , Vikas, Praveen , Zakharia, Yousef , Zaman, Qamar U., Brown, Alaina J. , Crispens, Marta Ann , Croessmann, Sarah , Davis, Elizabeth J. , Ding, Tan, Duda, Stephany N. , Hausrath, Daniel J. , Li, Xuanyi , Prescott, Lauren Shore , Wang, Lucy Lu , Aboulafia, David M. , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine , Painter, Corrie , Peters, Solange

Mayo Clinic

JAMA Oncology | August 17, 2023 | Volume: 9 | Issue: 10 | Pages: 1390

10.1001/jamaoncol.2023.2934 | PMID 37589970 Get It

ImportanceSystematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking.ObjectiveTo assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer.Design, Setting, and ParticipantsThis registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022.ExposureTreatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19.Main Outcomes and MeasuresMain outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up.ResultsOf 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing cancer (aRR, 1.43; 95% CI, 1.01-2.03), history of VTE (aRR, 3.10; 95% CI, 2.38-4.04), and high-risk site of cancer (aRR, 1.42; 95% CI, 1.14-1.75). Black patients had a higher risk of TEEs (aRR, 1.24; 95% CI, 1.03-1.50) than White patients. Patients with TEEs had high intensive care unit admission (46%) and mechanical ventilation (31%) rates. Relative risk of death in patients with TEEs was higher in those exposed to TOIs vs not (aRR, 1.12; 95% CI, 0.91-1.38) and was significantly associated with poor performance status (aRR, 1.77; 95% CI, 1.30-2.40) and active/progressing cancer (aRR, 1.55; 95% CI, 1.13-2.13).Conclusions and RelevanceIn this cohort study, relative risk of developing VTE was high among patients receiving TOIs and varied by the type of therapy, underlying risk factors, and demographics, such as race and ethnicity. These findings highlight the need for close monitoring and perhaps personalized thromboprophylaxis to prevent morbidity and mortality associated with COVID-19–related thromboembolism in patients with cancer.
Antidepressant-Associated Treatment Emergent Mania
Núñez, Nicolás A. , Özerdem, Ayşegül , Singh, Balwinder , Prieto, Miguel L. , Frye, Mark A. , Melhuish Beaupre, Lindsay, Singh, Balwinder , Ozerdem, Aysegul , Coombes, Brandon J. , Beaupre, Lindsay Melhuish , Romo‐Nava, Francisco , Gardea‐Resendez, Manuel , Veldić, Marin , Sánchez-Ruiz, Jorge A. , Cuéllar‐Barboza, Alfredo B. , Leung, Jonathan G. , McElroy, Susan L. , Biernacka, Joanna M.

Mayo Clinic

Journal of Clinical Psychopharmacology | August 16, 2023 | Volume: 43 | Issue: 5 | Pages: 428-433

10.1097/jcp.0000000000001747 | PMID 37683232 Get It

Abstract Background The purpose of this study was to review the association between the SLC6A4 5-HTTLPR polymorphism and antidepressant (AD)-associated treatment emergent mania (TEM) in bipolar disorder alongside starting a discussion on the merits of developing risk stratification models to guide when not to provide AD treatment for bipolar depression. Methods Studies that examined the association between clinical and genetic risk factors, specifically monoaminergic transporter genetic variation, and TEM were identified. A meta-analysis was performed using the odds ratio to estimate the effect size under the Der-Simonian and Laird model. Results Seven studies, referencing the SLC6A4 5-HTTLPR polymorphism and TEM (total N = 1578; TEM+ =594, TEM− = 984), of 142 identified articles were included. The time duration between the start of the AD to emergence of TEM ranged from 4 to 12 weeks. There was a nominally significant association between the s allele of the 5-HTTLPR polymorphism and TEM (odds ratio, 1.434; 95% confidence interval, 1.001–2.055; P = 0.0493; I 2 = 52%). No studies have investigated norepinephrine or dopamine transporters. Conclusion Although the serotonin transporter genetic variation is commercially available in pharmacogenomic decision support tools, greater efforts, more broadly, should focus on complete genome-wide approaches to determine genetic variants that may contribute to TEM. Moreover, these data are exemplary to the merits of developing risk stratification models, which include both clinical and biological risk factors, to guide when not to use ADs in bipolar disorder. Future studies will need to validate new risk models that best inform the development of personalized medicine best practices treating bipolar depression.
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Venneti, Sriram , Kawakibi, Abed Rahman , Ji, Sunjong , Waszak, Sebastian M. , Sweha, Stefan R. , Mota, Mateus , Pun, Matthew , Deogharkar, Akash , Chung, Chan , Tarapore, Rohinton S. , Ramage, Samuel , Chi, Andrew , Wen, Patrick Y. , Arrillaga‐Romany, Isabel , Batchelor, Tracy T. , Butowski, Nicholas , Shonka, Nicole , Hall, Matthew D. , Daghistani, Doured , Beccaria, Kévin , Umemura, Yoshie , Garton, Hugh , Franson, Andrea , Schwartz, Jonathan , Kachman, Maureen , Baum, Heidi , Burant, Charles , Mottl, Sophie L. , Cartaxo, Rodrigo T. , John, Vishal , Messinger, Dana , Peterson, Erik , Ravi, Karthik , Waugh, Alyssa , Walling, Dustin , Ding, Yujie , Xia, Ziyun , Hawes, Debra , Yang, Fusheng , Judkins, Alexander R. , Wahl, Daniel , Lyssiotis, Costas A. , Nava, Daniel de la , Eze, Augustine , Spitzer, Jasper , Schmidt, Susanne V. , Cain, Jason E. , Jiang, Li , Agar, Nathalie Y.R. , Zhao, Lili , Mody, Rajen , Kurokawa, Ryo , Yadav, Viveka Nand , Grill, Jacques , Kline, Cassie , Mueller, Sabine , Nazarian, Javad , Allen, Joshua E. , Odia, Yazmín , Butowski, Nicholas A , Sumrall, Ashley , Shonka, Nicole , Harrison, Rebecca A , de Groot, John , Mehta, Minesh P , Hall, Matthew D , Daghistani, Doured , Cloughesy, Timothy F , Ellingson, Benjamin M , Beccaria, Kevin , Varlet, Pascale , Kim, Michelle M , Umemura, Yoshie , Garton, Hugh , Franson, Andrea , Schwartz, Jonathan , Jain, Rajan , Kachman, Maureen , Baum, Heidi , Burant, Charles F , Mottl, Sophie L , Cartaxo, Rodrigo T , John, Vishal , Messinger, Dana , Qin, Tingting , Peterson, Erik , Sajjakulnukit, Peter , Ravi, Karthik , Waugh, Alyssa , Walling, Dustin , Ding, Yujie , Xia, Ziyun , Schwendeman, Anna , Hawes, Debra , Yang, Fusheng , Judkins, Alexander R , Wahl, Daniel , Lyssiotis, Costas A , de la Nava, Daniel , Alonso, Marta M , Eze, Augustine , Spitzer, Jasper , Schmidt, Susanne V , Duchatel, Ryan J , Dun, Matthew D , Cain, Jason E , Jiang, Li , Stopka, Sylwia A , Baquer, Gerard , Regan, Michael S , Filbin, Mariella G , Agar, Nathalie Y R , Zhao, Lili , Kumar-Sinha, Chandan , Mody, Rajen , Chinnaiyan, Arul , Kurokawa, Ryo , Pratt, Drew , Yadav, Viveka N , Grill, Jacques , Kline, Cassie , Mueller, Sabine , Resnick, Adam , Nazarian, Javad , Allen, Joshua E , Odia, Yazmin , Gardner, Sharon L , Koschmann, Carl , Tarapore, Rohinton S , Ji, Sunjong , Wen, Patrick Yung , Arrillaga‐Romany, Isabel , Sumrall, Ashley , Groot, John de , Mehta, Minesh P. , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Kim, Michelle M. , Jain, Rajan , Stopka, Sylwia A. , Baquer, Gerard , Regan, Michael S. , Koschmann, Carl

Mayo Clinic

Cancer Discovery | August 16, 2023 | Volume: 13 | Issue: 11 | Pages: 2370-2393

10.1158/2159-8290.cd-23-0131 | PMID 37584601 Get It

Abstract Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293
Enhancing diversity, equity, inclusion, and accessibility in eosinophilic gastrointestinal disease research: the consortium for eosinophilic gastrointestinal disease researchers’ journey
Chehade, Mirna , Furuta, Glenn T. , Abonia, J. Pablo , Aceves, Seema S. , Bose, Paroma , Dellon, Evan S. , Eickel, Grant, Gupta, Sandeep K. , Hiremath, Girish , Howard, Amari, Kesh, Susamita, Khoury, Paneez , Kocher, Kendra, Kodroff, Ellyn, Kyle, Shay, Mak, NaDea , McCoy, D. E., Mehta, Pooja , Menard‐Katcher, Paul , Paliana, Ally, Sable, Kathleen, Schmitt, Cara, Scott, Melissa, Strobel, Mary Jo, Zicarelli, Amy, Muir, Amanda B. , Wright, Benjamin L. , Bailey, Dominique D., Wright, Benjamin L , Klion, Amy D. , Collins, Margaret H. , Davis, Carla McGuire , Falk, Gary W. , Jensen, Elizabeth T. , McCoy, Dawn, Mukkada, Vincent A. , Rothenberg, Marc E. , Spergel, Jonathan M. , Wechsler, Joshua B , Yang, Guang‐Yu

Mayo Clinic

Therapeutic Advances in Rare Disease | August 14, 2023 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/26330040231180895 | PMID 37588777 Get It

In response to the social inequities that exist in health care, the NIH-funded Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) recently formed a diversity committee to examine systemic racism and implicit bias in the care and research of eosinophilic gastrointestinal diseases (EGIDs). Herein, we describe our process, highlighting milestones and issues addressed since the committee’s inception, which we hope will inspire other researchers to enhance diversity, equity, inclusion, and accessibility (DEIA) in their fields. Our journey began by establishing mission and vision statements to define the purpose of the committee. Regular discussion of diversity-related topics was incorporated into existing meetings and web-based materials were shared. This was followed by educational initiatives, including establishing a library of relevant publications and a speaker series to address DEIA topics. We then established a research agenda focused on the following actionable items: (1) to define what is known about the demographics of EGIDs by systematic review of population-based studies; (2) to develop a practical tool for reporting participant demographics to reduce bias in EGID literature; (3) to examine health disparities in the care of individuals with eosinophilic esophagitis who present to the emergency department with an esophageal food impaction; (4) to examine how access to a gastroenterologist affects the conclusions of published research examining the prevalence of pediatric eosinophilic esophagitis; and (5) to develop a model for examining the dimensions of diversity, and provide a framework for CEGIR’s ongoing projects and data capture. In addition to promoting consciousness of DEIA, this initiative has fostered inclusivity among CEGIR members and will continue to inspire positive changes in EGID care and research.
Effector response to necroptotic cell death: an ensemble of immune and stromal cells
Hughes, Lindsey D. , Nevin, James, Wang, Mamie, Pelorosso, Facundo, Leighton, Jonathan A. , Altun, Osman, Kluger, Yuval , Rothlin, Carla V. , Ghosh, Sourav

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 72.39-72.39

10.4049/jimmunol.210.supp.72.39 Get It

Abstract Cell death manifests through a panoply of molecular pathways. We postulated that the tissue effector response to cellular corpses is similarly diverse. Apoptotic cell death in the lung, in the context of helminth infection and an IL-4-rich environment, is sensed by macrophages to direct resolution of inflammation and a tissue repair gene expression program. Apoptotic cell death, however, is commonplace in the gut and integral to homeostatic tissue renewal in this organ. Another specific molecularly-executed cell death modality – necroptosis – has been reported in the gut in settings of non-resolving inflammation and tissue damage, such as in inflammatory bowel disease. Here we report the discovery of an effector response to necroptotic corpses (NC). Using a chemo-genetic approach to specifically trigger necroptosis in the intestinal epithelium in vivo, we compiled an atlas of transcriptomic changes at a single-cell level and compared this to inflammatory and resolving injury models. Fibroblasts and macrophages, upon encounter with NC, displayed an excessive inflammatory response. Fibroblasts are the major stromal cells that play an essential role in tissue healing by undergoing fibroblast to myofibroblast transition under the influence of TGF-β. This step is a critical event in wound healing as the contractile forces generated by myofibroblasts bring the two apposed edges of the wounded tissue together for wound closure. Exposure to NC prevented this myofibroblast transition. Taken together, these findings point to an invariant code that informs effector tissue responses based on the type, context, and sensor of cell death.
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Carpenter, Elizabeth Lee, Decar, Spencer Van , McCarthy, Patrick M. , Vreeland, Timothy J. , Valdera, Franklin, Tiwari, Ankur, Hale, Diane F. , Bohan, Phillip Kemp, Hickerson, Annelies T. , Smolinsky, Todd , Thomas, Katryna, Cindass, Jessica L., Hyngstrom, John , Berger, Adam C. , Shaheen, Montaser , Yu, Xianzhong, Wagner, Thomas E., Faries, Mark B. , Peoples, George E. , Van Decar, Spencer , McCarthy, Patrick , Vreeland, Timothy J , Jakub, James, Adams, Alexandra M. , O’Shea, Anne E. , Chick, Robert C. , Clifton, Guy T. , Bohan, Phillip M. Kemp , Jakub, James W. , Sussman, Jonathan

Mayo Clinic

Journal for ImmunoTherapy of Cancer | August 3, 2023 | Volume: 11 | Issue: 8 | Pages: e006665

10.1136/jitc-2023-006665 | PMID 37536936 Get It

Background The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor lysate (TL). The tumor lysate, particle only (TLPO) vaccine uses autologous TL-loaded YCWPs coated with silicate for in vivo DC loading. Here we report the 36-month prespecified analyses of this prospective, randomized, double-blind trial investigating the ability of the TLPO and TLPLDC (±granulocyte-colony stimulating factor (G-CSF)) vaccines to prevent melanoma recurrence in high-risk patients. Methods Patients with clinically disease-free stage III/IV melanoma were randomized 2:1 initially to TLPLDC versus placebo (n=124) and subsequently TLPO versus TLPLDC (n=63). All patients were randomized and blinded; however, the placebo control arm was replaced in the second randomization scheme with another novel vaccine; some analyses in this paper therefore reflect a combination of the two randomization schemes. Patients receiving the TLPLDC vaccine were further divided by their method of DC harvest (with or without G-CSF pretreatment); this was not randomized. The use of standard of care checkpoint inhibitors was not stratified between groups. Safety was assessed and Kaplan-Meier and log-rank analyses compared disease-free (DFS) and overall survival (OS). Results After combining the two randomization processes, a total of 187 patients were allocated between treatment arms: placebo (n=41), TLPLDC (n=103), or TLPO (n=43). The allocation among arms created by the addition of patients from the two separate randomization schemes does not reflect concurrent randomization among all treatment arms. TLPLDC was further divided by use of G-CSF in DC harvest: no G-CSF (TLPLDC) (n=47) and with G-CSF (TLPLDC+G) (n=56). Median follow-up was 35.8 months. Only two patients experienced a related adverse event ≥grade 3, one each in the TLPLDC+G and placebo arms. DFS was 27.2% (placebo), 55.4% (TLPLDC), 22.9% (TLPLDC+G), and 60.9% (TLPO) (p<0.001). OS was 62.5% (placebo), 93.6% (TLPLDC), 57.7% (TLPLDC+G), and 94.6% (TLPO) (p=0.002). Conclusions The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial. Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial. Trial registration number NCT02301611 .
Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
Huamán, Moisés A. , Patel, Bela , Marshall, Christi E., Yarava, Anusha , Heath, Sonya L. , Fukuta, Yuriko , Blair, Janis E. , Spivak, Emily S , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Ram, Malathi , Das, Piyali, Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Laeyendecker, Oliver , Ehrhardt, Stephan , Lau, Bryan , Baksh, Sheriza , Shade, David , Ou, Jiangda , Gniadek, Thomas J. , Ziman, Alyssa , Bloch, Evan M. , Gerber, Jonathan M. , Ziman, Alyssa , Bloch, Evan M , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Laeyendecker, Oliver , Raval, Jay S. , Paxton, James H , Mosnaim, Giselle S , Anjan, Shweta , Meisenberg, Barry R. , Levine, Adam C , Shenoy, Aarthi , Currier, Judith S. , Broderick, Patrick B., Sutcliffe, Catherine G , Zand, Martin S. , Kassaye, Seble , Wang, Ying , Ford, Daniel E , Pekosz, Andrew , Klein, Sabra L , Casadevall, Arturo , Hanley, Daniel F. , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Transfusion | August 3, 2023 | Volume: 63 | Issue: 9 | Pages: 1639-1648

10.1111/trf.17485 | PMID 37534607 Get It

AbstractBackgroundCOVID‐19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials.Study Design and MethodsWe analyzed data pertaining to transfusion‐related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders.ResultsThe combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 (4.6%) characterized by mild, allergic‐type findings of urticaria, and/or pruritus consistent with minor allergic transfusion reactions; the other reported events were attributed to the patients' underlying disease, COVID‐19, or vasovagal in nature. We found no difference in the likelihood of allergic transfusion reactions between those receiving CCP versus control plasma (adjusted odds ratio [AOR], 0.75; 95% CI, 0.43–1.31). Risk of urticaria and/or pruritus increased with a pre‐existing diagnosis of asthma (AOR, 2.33; 95% CI, 1.16–4.67). We did not observe any CCP‐attributed antibody disease enhancement in participants with COVID‐19 or increased risk of infection. There were no life‐threatening severe transfusion reactions and no patients required hospitalization related to transfusion‐associated complications.DiscussionOutpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID‐19.